HLA-A and cancer: Prognostic value associated with CD8+ TIL represents the current dogma of adaptive immune signature against cancers.13,14,37 Here, circulating CD8+ T-cell responses against HLA-A*0201 and HLA-B7-restricted peptides from telomerase were detected in 13% (8/60) of patients using the ELISpot assay (not shown).